Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Burkitt Lymphoma | 1 | 2018 | 15 | 0.77 | Why? |
| Cell Wall | 2 | 2017 | 62 | 0.74 | Why? |
| Corynebacterium Infections | 1 | 2018 | 26 | 0.74 | Why? |
| Ixodidae | 1 | 2018 | 37 | 0.73 | Why? |
| Corynebacterium | 1 | 2018 | 47 | 0.73 | Why? |
| Biofilms | 2 | 2018 | 304 | 0.70 | Why? |
| Sarcoma, Kaposi | 1 | 2018 | 97 | 0.68 | Why? |
| Casein Kinase II | 1 | 2017 | 120 | 0.67 | Why? |
| Phlebovirus | 1 | 2018 | 106 | 0.66 | Why? |
| Bunyaviridae Infections | 1 | 2018 | 107 | 0.65 | Why? |
| Candidemia | 2 | 2018 | 353 | 0.62 | Why? |
| Candida | 2 | 2018 | 425 | 0.62 | Why? |
| Candida albicans | 1 | 2017 | 217 | 0.62 | Why? |
| Blood Culture | 1 | 2018 | 308 | 0.60 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 533 | 0.47 | Why? |
| Staphylococcal Infections | 5 | 2018 | 1099 | 0.40 | Why? |
| Scrub Typhus | 2 | 2018 | 68 | 0.34 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 711 | 0.33 | Why? |
| Republic of Korea | 16 | 2021 | 5858 | 0.31 | Why? |
| Brain Diseases | 1 | 2018 | 1463 | 0.31 | Why? |
| Antifungal Agents | 3 | 2018 | 1828 | 0.25 | Why? |
| Acinetobacter Infections | 2 | 2017 | 273 | 0.23 | Why? |
| Infectious Disease Medicine | 2 | 2020 | 311 | 0.22 | Why? |
| Taenia saginata | 1 | 2019 | 5 | 0.21 | Why? |
| Taeniasis | 1 | 2019 | 9 | 0.21 | Why? |
| Arachnid Vectors | 1 | 2018 | 24 | 0.19 | Why? |
| Candida glabrata | 1 | 2018 | 50 | 0.18 | Why? |
| Chitin | 1 | 2017 | 32 | 0.18 | Why? |
| Methicillin | 1 | 2017 | 73 | 0.17 | Why? |
| Candida tropicalis | 1 | 2017 | 21 | 0.17 | Why? |
| Fluconazole | 1 | 2018 | 145 | 0.17 | Why? |
| Daptomycin | 1 | 2017 | 64 | 0.17 | Why? |
| Drug Resistance, Fungal | 1 | 2018 | 191 | 0.16 | Why? |
| Chemoembolization, Therapeutic | 1 | 2018 | 144 | 0.16 | Why? |
| Bacteremia | 3 | 2018 | 1372 | 0.16 | Why? |
| Natural Killer T-Cells | 1 | 2018 | 191 | 0.16 | Why? |
| Staphylococcus aureus | 2 | 2018 | 844 | 0.16 | Why? |
| Cerebrospinal Fluid | 1 | 2018 | 234 | 0.16 | Why? |
| Calcitonin | 1 | 2018 | 201 | 0.16 | Why? |
| beta-Lactams | 1 | 2018 | 210 | 0.16 | Why? |
| Central Venous Catheters | 1 | 2017 | 188 | 0.14 | Why? |
| Neutropenia | 1 | 2018 | 388 | 0.14 | Why? |
| Cross Infection | 5 | 2021 | 8675 | 0.14 | Why? |
| Carbapenems | 2 | 2017 | 343 | 0.13 | Why? |
| Candidiasis | 1 | 2018 | 334 | 0.13 | Why? |
| Acinetobacter | 1 | 2013 | 58 | 0.13 | Why? |
| Acinetobacter baumannii | 1 | 2017 | 378 | 0.13 | Why? |
| Catheter Ablation | 1 | 2018 | 438 | 0.13 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.12 | Why? |
| HIV Infections | 1 | 2018 | 11620 | 0.12 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2017 | 572 | 0.12 | Why? |
| Hospitals, University | 3 | 2021 | 4173 | 0.12 | Why? |
| Microbial Sensitivity Tests | 5 | 2018 | 2886 | 0.12 | Why? |
| Anti-Bacterial Agents | 6 | 2018 | 10083 | 0.12 | Why? |
| Influenza B virus | 1 | 2017 | 815 | 0.11 | Why? |
| Influenza Vaccines | 2 | 2017 | 2941 | 0.11 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.10 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.10 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 1458 | 0.09 | Why? |
| Sexual and Gender Minorities | 1 | 2018 | 1019 | 0.09 | Why? |
| Orientia tsutsugamushi | 2 | 2018 | 45 | 0.09 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1573 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2018 | 1222 | 0.09 | Why? |
| Disaster Planning | 1 | 2020 | 1680 | 0.09 | Why? |
| Drug Resistance, Bacterial | 2 | 2017 | 1414 | 0.08 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.08 | Why? |
| Killer Cells, Natural | 1 | 2017 | 2093 | 0.08 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.08 | Why? |
| Aged | 14 | 2021 | 215776 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2018 | 1666 | 0.08 | Why? |
| Male | 20 | 2021 | 367725 | 0.08 | Why? |
| Methicillin Resistance | 1 | 2005 | 77 | 0.07 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.07 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.07 | Why? |
| Female | 19 | 2021 | 380317 | 0.07 | Why? |
| Phylogeny | 3 | 2019 | 13341 | 0.07 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.07 | Why? |
| Disease Outbreaks | 3 | 2021 | 27595 | 0.07 | Why? |
| Korea | 2 | 2018 | 89 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.06 | Why? |
| Humans | 29 | 2021 | 930598 | 0.06 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.06 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.06 | Why? |
| Physicians | 1 | 2020 | 4214 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Electron Transport Complex IV | 1 | 2019 | 21 | 0.05 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Helminth Proteins | 1 | 2019 | 32 | 0.05 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.05 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.05 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.05 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.04 | Why? |
| Echinocandins | 1 | 2018 | 139 | 0.04 | Why? |
| Amphotericin B | 1 | 2018 | 256 | 0.04 | Why? |
| Hemagglutination Inhibition Tests | 1 | 2017 | 191 | 0.04 | Why? |
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 146 | 0.04 | Why? |
| Interleukin-12 | 1 | 2017 | 156 | 0.04 | Why? |
| Technology, Pharmaceutical | 1 | 2017 | 82 | 0.04 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.04 | Why? |
| Interleukin-18 | 1 | 2017 | 328 | 0.04 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.04 | Why? |
| Vancomycin | 1 | 2017 | 328 | 0.03 | Why? |
| Colistin | 1 | 2017 | 217 | 0.03 | Why? |
| Lectins, C-Type | 1 | 2017 | 405 | 0.03 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.03 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.03 | Why? |
| Cell Culture Techniques | 1 | 2017 | 704 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Hospitals | 2 | 2018 | 11793 | 0.03 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.03 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.03 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.03 | Why? |
| Animals | 2 | 2019 | 78931 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Genetic Variation | 1 | 2005 | 3919 | 0.03 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.03 | Why? |
| Adult | 8 | 2021 | 244371 | 0.03 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.03 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.03 | Why? |
| Intensive Care Units | 1 | 2017 | 29594 | 0.03 | Why? |
| Sentinel Surveillance | 1 | 2017 | 1093 | 0.02 | Why? |
| Vaccines, Inactivated | 1 | 2017 | 1562 | 0.02 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.02 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| Ribavirin | 1 | 2015 | 1182 | 0.02 | Why? |
| Genotype | 2 | 2013 | 4697 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.02 | Why? |
| Interferon-alpha | 1 | 2015 | 1442 | 0.02 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.02 | Why? |
| Bacterial Typing Techniques | 1 | 2005 | 273 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2013 | 4260 | 0.02 | Why? |
| Patient Isolation | 1 | 2017 | 3182 | 0.02 | Why? |
| Antiviral Agents | 1 | 2015 | 41703 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2015 | 7268 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Lopinavir | 1 | 2015 | 4308 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Ritonavir | 1 | 2015 | 4212 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.01 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.01 | Why? |
| Masks | 1 | 2021 | 8528 | 0.01 | Why? |
| Bacterial Proteins | 1 | 2005 | 1318 | 0.01 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2015 | 8843 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2017 | 51949 | 0.00 | Why? |
Jung's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(172)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(99)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_